目的了解慢性间质性肾炎(chron ic in terstitia l nephritis,C IN)患者肾组织中NGAL的表达及NGAL与肾小管-间质病理损害程度的关系。方法免疫组化观察正常肾组织和C IN患者肾组织NGAL的表达,以及NGAL阳性强度与小管-间质病理损害程度...目的了解慢性间质性肾炎(chron ic in terstitia l nephritis,C IN)患者肾组织中NGAL的表达及NGAL与肾小管-间质病理损害程度的关系。方法免疫组化观察正常肾组织和C IN患者肾组织NGAL的表达,以及NGAL阳性强度与小管-间质病理损害程度的关系。结果C IN患者肾组织表达NGAL较正常组增强;其小管NGAL阳性强度与小管-间质病理损害程度呈负相关。结论NGAL在C IN肾小管-间质病理损害中起重要作用。展开更多
1 Introduction In recent years, significant progress has been made in applying immunotoxin (IT)in the therapy of leukemia and marrow transplantation. By 1990, several ITs havebeen put into clinical trials under the pe...1 Introduction In recent years, significant progress has been made in applying immunotoxin (IT)in the therapy of leukemia and marrow transplantation. By 1990, several ITs havebeen put into clinical trials under the permission of FDA (Foodand Drug Administration, USA).展开更多
文摘目的了解慢性间质性肾炎(chron ic in terstitia l nephritis,C IN)患者肾组织中NGAL的表达及NGAL与肾小管-间质病理损害程度的关系。方法免疫组化观察正常肾组织和C IN患者肾组织NGAL的表达,以及NGAL阳性强度与小管-间质病理损害程度的关系。结果C IN患者肾组织表达NGAL较正常组增强;其小管NGAL阳性强度与小管-间质病理损害程度呈负相关。结论NGAL在C IN肾小管-间质病理损害中起重要作用。
基金Bio-High Technology Program from the State Commission of Science and Technology, PRC.
文摘1 Introduction In recent years, significant progress has been made in applying immunotoxin (IT)in the therapy of leukemia and marrow transplantation. By 1990, several ITs havebeen put into clinical trials under the permission of FDA (Foodand Drug Administration, USA).